Other (Income) Expense, Net

12 Months Ended

Dec. 31, 2020

Other Income and Expenses [Abstract]

Other (income) expense, net, consisted of:


Years Ended December 31	2020		2019		2018
Interest income	$	(59)	$	(274)	$	(343)
Interest expense	831		893		772
Exchange losses	145		187		145
Income from investments in equity securities, net (1)	(1,338)		(170)		(324)
Net periodic defined benefit plan (credit) cost other than service cost	(339)		(545)		(512)
Other, net	(126)		48		(140)
	$	(886)	$	139	$	(402)

(1) Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while ownership interests in investment funds are accounted for on a one quarter lag.

Other, net (as presented in the table above) in 2019 includes $162 million of goodwill impairment charges related to certain businesses in the Healthcare Services segment (see Note 8).

Other, net in 2018 includes a gain of $115 million related to the settlement of certain patent litigation, income of $99 million related to AstraZeneca’s option exercise in 2014 in connection with the termination of the Company’s relationship with AstraZeneca LP (AZLP), and a gain of $85 million resulting from the receipt of a milestone payment for an out-licensed migraine clinical development program. Other, net in 2018 also includes $144 million of goodwill impairment charges related to certain businesses in the Healthcare Services segment (see Note 8), as well as $41 million of charges related to the write-down of assets held for sale to fair value in anticipation of the dissolution of the Company’s joint venture with Supera Farma Laboratorios S.A. in Brazil.

Interest paid was $822 million in 2020, $841 million in 2019 and $777 million in 2018.